NASDAQ · Biotechnology

LBRX (LBRX) Stock

$48.11 -0.15% NASDAQ: LBRX Healthcare

Valuation

MetricValue
Price$48.11
Market Cap$1.38B
P/E Ratio-29.66
P/B Ratio2.83
P/S Ratio0.00
EPS (TTM)$-1.00
52-Week High$48.11
52-Week Low$13.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-8.31%
ROA-7.99%
ROCE-9.97%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio44.00

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-3.0M$-11.0M$-65.0M$-30.0M
Net Profit$-14.0M$-6.0M$-63.0M$-25.0M
EPS$-4.05$-1.77$-17.83$-1.00
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets$21.0M$46.0M$34.0M$313.0M
Total Liabilities$50.0M$80.0M$128.0M$12.0M
Cash$21.0M$15.0M$23.0M$250.0M
Borrowings$24.0M$0$4.0M$4.0M

Latest News

LB Pharmaceuticals Expects Phase-3 Schizophrenia Study's Topline Data in H1 2027 MT Newswires · Jul 22, 2026 LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia GlobeNewswire · Jul 22, 2026 Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls The Fly · Jul 21, 2026 BMO Capital Initiates LB Pharmaceuticals at Outperform With $46 Price Target MT Newswires · Jul 21, 2026 LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 10, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-3.0M$-12.0M$-53.0M$-35.0M
Investing Cash Flow$0$-28.0M$22.0M$-40.0M
Financing Cash Flow$-3.0M$-2.0M$-2.0M$0
Net Cash Flow$20.0M$-6.0M$8.0M$227.0M
Free Cash Flow$-3.0M$-12.0M$-54.0M$-35.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-6.50%
Quick Ratio35.68
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
ANNX $5.37 +0.75% -3.71 $879.83M 0.00%
AURA $7.06 -1.40% -4.35 $453.25M 0.00%
AUTLAutolus Therapeutics plc $1.46 -13.61% -1.35 — 0.00%
DBVTDBV Technologies S.A. $15.84 +0.83% -3.27 $378.92M 0.00%

About LBRX

LBRX is led by CEO Heather D. Turner, publicly traded since 2025.

LBRX stock trades at $48.11 with a market capitalization of $1.38B. The stock is valued at a price-to-earnings (P/E) ratio of -29.66, price-to-book of 2.83, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $13.36 and $48.11, and currently trades at its 52-week high.

On profitability, LBRX generates a return on equity (ROE) of -8.31%, return on capital employed of -9.97%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides